132673NUVEC a platform technology for the vaccine deliveryClosedFeasibility StudiesInnovate UKNanotechnology platforms, including N4’s propriety NUVEC, are being investigated as vaccine carriers, adjuvants, and drug delivery systems. DNA vaccination indicates great potential for combating a variety of diseases including cancer. Safe and efficient delivery of plasmid DNA to initiate immune responses remains a major barrier in bringing DNA vaccination into human medicine. N4’s NUVEC is a novel platform capable of delivering a range of therapeutic biomolecules whilst simultaneously stimulating the immune system.